Neurology · Antidepressant
The FDA's acceptance of the ANDA for Desvenlafaxine Succinate by Platinum signifies a potential shift in the competitive landscape of the antidepressant market. Pharma strategy teams must evaluate the implications for pricing and market share as generic options become available.
Multi-agent research across ingested FDA, EMA, MHRA, PMDA, PubMed, ClinicalTrials.gov, company documents, and Humanexa signals.
Last run 7/24/2026, 12:31:13 AM
Assessment confidence: 64% · The main uncertainty is timing and magnitude of competitive and regulatory follow-through.
The FDA's acceptance of the ANDA for Desvenlafaxine Succinate by Platinum signifies a potential shift in the competitive landscape of the antidepressant market. Pharma strategy teams must evaluate the implications for pricing and market share as generic options become available. Regulatory context from FDA (FDA AP — DESVENLAFAXINE SUCCINATE (SUPPL)) supports the near-term read. Assessment grounded in 18 ranked evidence items (7 high-relevance).
Portfolio teams should assess the impact of this new generic entry on market share and pricing strategies for similar products. The strongest clinical anchor is Hydrus® Microstent New Enrollment Post-Approval Study (ClinicalTrials.gov), moderate corpus alignment. In Neurology · Antidepressant, 8 regulatory and 1 competitive items passed relevance filtering for Platinum.
The most relevant competitive pressure comes from FDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment (Humanexa Signals) — sponsor/company relevance (roche). This acceptance may increase competition in the antidepressant market, particularly against existing branded products.
Regulatory risk is concentrated around FDA AP — DESVENLAFAXINE SUCCINATE (SUPPL) (FDA). Entity match (platinum); Regulatory pathway relevance (nda). While the ANDA acceptance is a positive step, the timeline for final approval and market entry remains critical for assessing regulatory compliance and market readiness.
FDA AP — DESVENLAFAXINE SUCCINATE (SUPPL)
FDAhigh relevance
Entity match (platinum); Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — PRUCALOPRIDE SUCCINATE (ORIG)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — METHYLPREDNISOLONE SODIUM SUCCINATE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — DOXYLAMINE SUCCINATE AND PYRIDOXINE HYDROCHLORIDE (SUPPL)
FDAhigh relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — ADRENALIN (SUPPL)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View sourceFDA AP — TRAMADOL HYDROCHLORIDE (ORIG)
FDAmedium relevance
Regulatory pathway relevance (nda)
FDA document
View sourceHydrus® Microstent New Enrollment Post-Approval Study
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceManagement of Abdominal Post-surgical Scar With Ozoaqua Versus Standard Care
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceAn Open-Label, Bayesian Adaptive Phase II Clinical Study in HR+/HER2- Advanced Breast Cancer After Progression on Standard Therapy
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceModified Mini-PCNL Versus Standard PCNL for Complex Kidney Stones
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceComparative Effectiveness Research Trial for Antidepressant Incomplete and Non-responders With TRD
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceMYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)
ClinicalTrials.govmedium relevance
Moderate corpus alignment
FDA document
View sourceFDA Accepts Roche's Gazyva for Systemic Lupus Erythematosus Treatment
Humanexa Signalshigh relevance
Sponsor/company relevance (Roche)
Colorectal cancer care in Uganda: a narrative review and case-based health needs assessment from Mbarara Regional Referral Hospital.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEffects of caffeine gum on same-day and subsequent neuromuscular performance under a standardized resistance-priming condition in male basketball players.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourceEffectiveness and safety of brentuximab vedotin-containing regimen versus standard chemotherapy in relapsed or refractory Hodgkin lymphoma: a multicenter cohort study.
PubMedmedium relevance
Moderate corpus alignment
FDA document
View sourcePrecedents · guidance
Loading regulatory precedents…
View full regulatory analysisCompetitors · threats
Loading competitive findings…
View full competitive analysisThe FDA's acceptance of the ANDA for Desvenlafaxine Succinate by Platinum signifies a potential shift in the competitive landscape of the antidepressant market. Pharma strategy teams must evaluate the implications for pricing and market share as generic options become available.
The introduction of a generic version could pressure pricing and market share for existing branded antidepressants, impacting revenue streams.
While the ANDA acceptance is a positive step, the timeline for final approval and market entry remains critical for assessing regulatory compliance and market readiness.
Monitor the timeline for final approval and market entry of the generic product.
Track for follow-up milestones; no immediate action required.